Innate Pharma (NASDAQ:IPHA) and SOPHiA GENETICS (NASDAQ:SOPH) Financial Comparison

SOPHiA GENETICS (NASDAQ:SOPH) and Innate Pharma (NASDAQ:IPHA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, valuation, profitability, risk and dividends.

Earnings and Valuation

This table compares SOPHiA GENETICS and Innate Pharma”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SOPHiA GENETICS	$62.37 million	3.29	-$78.98 million	($1.09)	-2.88
Innate Pharma	$66.71 million	2.21	-$8.19 million	N/A	N/A

Innate Pharma has higher revenue and earnings than SOPHiA GENETICS.

Profitability

This table compares SOPHiA GENETICS and Innate Pharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
SOPHiA GENETICS	-110.71%	-55.06%	-38.33%
Innate Pharma	N/A	N/A	N/A

Analyst Recommendations

This is a breakdown of current ratings for SOPHiA GENETICS and Innate Pharma, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SOPHiA GENETICS	0	1	4	0	2.80
Innate Pharma	0	0	1	1	3.50

SOPHiA GENETICS currently has a consensus target price of $7.40, indicating a potential upside of 135.67%. Innate Pharma has a consensus target price of $11.50, indicating a potential upside of 554.90%. Given Innate Pharma’s stronger consensus rating and higher possible upside, analysts plainly believe Innate Pharma is more favorable than SOPHiA GENETICS.

Risk and Volatility

SOPHiA GENETICS has a beta of 1, meaning that its share price has a similar volatility profile to the S&P 500.Comparatively, Innate Pharma has a beta of 0.27, meaning that its share price is 73% less volatile than the S&P 500.

Insider & Institutional Ownership

31.6% of SOPHiA GENETICS shares are owned by institutional investors. Comparatively, 0.2% of Innate Pharma shares are owned by institutional investors. 4.9% of SOPHiA GENETICS shares are owned by insiders. Comparatively, 31.9% of Innate Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Innate Pharma beats SOPHiA GENETICS on 9 of the 13 factors compared between the two stocks.

About SOPHiA GENETICS

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Rolle, Switzerland.

About Innate Pharma

Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.